NovaScan
BETTER SCIENCE
BETTER CANCER DETECTION
Easy to use, ex vivo and in vivo cancer detection that provides instantaneous, highly accurate results, without capital equipment.
MarginScan™
Real-Time Surgical Margin Assessment
MarginScan™ is a compact device that combines biospectral impedance and AI/ML to detect and localize cancer at the margins of surgical excisions—in seconds.
MarginScan is non-destructive, requires no dedicated pathology resources, and does not interfere with standard histopathology, which may be performed afterward if desired. The technology enables healthy tissue–sparing surgery, improved workflow predictability, and the potential for better clinical and economic outcomes.
Proven Track Record
CPRIT Grant
Awarded by the Cancer Prevention and Research Institute of Texas to advance MarginScan™ for breast cancer surgery and FDA clearance.
Manufacturing & Distribution
MarginScan™ manufactured by PHC Group (TSE: 6523). Exclusive U.S. distribution letter of intent signed with Epredia.
Patients Evaluated
Clinical trials across multiple cancer types with 91%-100% sensitivity and 85%-100% specificity. Results published in peer-reviewed journals.
Our Technology
Cole Relaxation Frequency
Our core technology leverages the Cole relaxation frequency, which is several orders of magnitude larger for cancerous cells than non-cancerous cells. This fundamental difference provides an unmatched dynamic range in diagnostics.
Learn more about the Novascan Difference →Clinical Results
NovaScan has completed extensive clinical work across multiple cancer types, with results published in peer-reviewed journals. Our technology demonstrates exceptional performance in sensitivity and specificity across various applications.
View Clinical Results